Adenocarcinoma of the Gastroesophageal JunctionPhase 2NCT01498289
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
A Phase 2 study testing FOLFOX regimen, docetaxel and fluorouracil in people with Adenocarcinoma of the Gastroesophageal Junction and Esophageal Cancer, run by SWOG Cancer Research Network at 508 sites in United States.
Trial summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Combining more than one drug may kill more tumor cells. Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- What is being tested?
- FOLFOX regimen, docetaxel and fluorouracil
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 213 participants
- Where
- 508 sitesUnited States
- Study dates
- Feb 2012to 19 Sep 2019
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Patients must have unresectable advanced or metastatic histologically or cytologically confirmed adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJ)
- Patients must not have received treatment for metastatic or unresectable disease
- Patients must not have brain metastases
- Patients must have measurable and/or non-measurable disease
- Patients who have had HER-2 expression testing prior to patient consent to this study must be HER-2 negative; if HER-2 expression has not been tested prior to patient consent to this study, a second specimen must be submitted for HER-2 expression; if the specimen is HER-2 positive (or if HER-2 could not be evaluated), the patient will not be randomized
- Patients must have completed any prior neoadjuvant and adjuvant therapy for resectable disease at least 180 days prior to registration
PATIENT CHARACTERISTICS:
- Zubrod performance status of 0-1
- Hemoglobin ≥ 9 g/dL
- Absolute neutrophil count (ANC) ≥ 1,500/mcL
- Platelets ≥ 100,000/mcL
- Total bilirubin ≤ 1.5 mg/dL regardless of whether patients have liver involvement secondary to tumor
- AST and ALT both ≤ 3 times institutional upper limit of normal (IULN) unless the liver is involved with tumor, in which case both AST and ALT must be ≤ 5 times IULN
- Serum creatinine < 1.5 mg/dL within 28 days prior to registration AND/OR calculated creatinine clearance > 60 mL/min
- Patients must not have motor or sensory neuropathy > Grade 1 using CTCAE version 4.0
- Patients must not be pregnant or nursing; women and men of reproductive potential must have agreed to use an effective contraceptive method
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for five years
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- All palliative radiation therapy alone must be completed at least 14 days prior to registration
- Patient must have no plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other type of therapy for treatment of cancer while on this protocol treatment
Trial locations and contacts
508 sites in 1 country.
300 sites in 1 country
United States300 sites
Oncare Hawaii Inc-Pali Momi
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
Bixby Medical Center
Adrian, Michigan, 49221
Hickman Cancer Center
Adrian, Michigan, 49221
Summa Akron City Hospital/Cooper Cancer Center
Akron, Ohio, 44304
Akron General Medical Center
Akron, Ohio, 44307
Phoebe Putney Memorial Hospital
Albany, Georgia, 31701
University of New Mexico
Albuquerque, New Mexico, 87106
Lehigh Valley Hospital
Allentown, Pennsylvania, 18105
Saint Anthony's Health
Alton, Illinois, 62002
Mary Greeley Medical Center
Ames, Iowa, 50010
McFarland Clinic PC-William R Bliss Cancer Center
Ames, Iowa, 50010
Cancer Care Center at Island Hospital
Anacortes, Washington, 98221
AnMed Health Cancer Center
Anderson, South Carolina, 29621
AnMed Health Hospital
Anderson, South Carolina, 29621
Veteran's Administration Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106-0995
Michigan Cancer Research Consortium Community Clinical Oncology Program
Ann Arbor, Michigan, 48106
University of Michigan University Hospital
Ann Arbor, Michigan, 48109
University of Michigan
Ann Arbor, Michigan, 48109
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
Randolph Hospital
Asheboro, North Carolina, 27203
Sutter Auburn Faith Hospital
Auburn, California, 95602
Auburn Regional Medical Center
Auburn, Washington, 98001
Harold Alfond Center for Cancer Care
Augusta, Maine, 04330
The Medical Center of Aurora
Aurora, Colorado, 80012
Greater Baltimore Medical Center
Baltimore, Maryland, 21204
Eastern Maine Medical Center
Bangor, Maine, 04401
Summa Barberton Hospital
Barberton, Ohio, 44203
Ochsner Health Center-Summa
Baton Rouge, Louisiana, 70809
Bronson Battle Creek
Battle Creek, Michigan, 49017
Overlake Hospital Medical Center
Bellevue, Washington, 98004
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Sanford Clinic North-Bemidgi
Bemidji, Minnesota, 56601
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Constantinou, Costas L MD (UIA Investigator)
Bettendorf, Iowa, 52722
Hematology Oncology Associates-Quad Cities
Bettendorf, Iowa, 52722
Spectrum Health Big Rapids Hospital
Big Rapids, Michigan, 49307
Montana Cancer Consortium CCOP
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Billings Clinic
Billings, Montana, 59107-7000
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61701
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Central Care Cancer Center-Carrie J Babb Cancer Center
Bolivar, Missouri, 65613
McFarland Clinic PC-Boone
Boone, Iowa, 50036
Boulder Community Hospital
Boulder, Colorado, 80301
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Toledo Clinic Cancer Centers-Bowling Green
Bowling Green, Ohio, 43402
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, 98310
Highline Medical Center-Main Campus
Burien, Washington, 98166
Mills - Peninsula Hospitals
Burlingame, California, 94010
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Graham Hospital Association
Canton, Illinois, 61520
Illinois CancerCare-Canton
Canton, Illinois, 61520
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Memorial Hospital
Carthage, Illinois, 62321
Rocky Mountain Oncology
Casper, Wyoming, 82609
Centralia Oncology Clinic
Centralia, Illinois, 62801
Providence Regional Cancer System-Centralia
Centralia, Washington, 98531
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Roper Hospital
Charleston, South Carolina, 29401
Charleston Hematology Oncology Associates-Roper
Charleston, South Carolina, 29403
Lowcountry Hematology Oncology PA-Charleston
Charleston, South Carolina, 29406
Charleston Hematology Oncology Associates PA-St. Francis
Charleston, South Carolina, 29414
Lowcountry Hematology Oncology PA-West Ashley
Charleston, South Carolina, 29414
Hematology and Oncology Associates
Chicago, Illinois, 60611
Northwestern University
Chicago, Illinois, 60611
University of Illinois
Chicago, Illinois, 60612
Oncology Hematology Care Inc-Mercy West
Cincinnati, Ohio, 45211
Oncology and Hematology Care Inc-Taft
Cincinnati, Ohio, 45219
Oncology Hematology Care Inc - Anderson
Cincinnati, Ohio, 45230
Oncology Hematology Care Inc - Kenwood
Cincinnati, Ohio, 45236
Oncology Hematology Care Inc-Blue Ash
Cincinnati, Ohio, 45242
University of Cincinnati
Cincinnati, Ohio, 45267
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
MetroHealth Medical Center
Cleveland, Ohio, 44109
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, 28328
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
John B Amos Cancer Center
Columbus, Georgia, 31904
Ohio State University Medical Center
Columbus, Ohio, 43210
New Hampshire Oncology-Hematology PA
Concord, New Hampshire, 03301
Oncology Hematology Care Inc-Crestview
Crestview Hills, Kentucky, 41017
Genesis Medical Center - East Campus
Davenport, Iowa, 52803
Sutter Davis Hospital
Davis, California, 95616
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital - Dayton
Dayton, Ohio, 45406
Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Health Center
Dayton, Ohio, 45415
Dayton CCOP
Dayton, Ohio, 45420
Oakwood Hospital and Medical Center
Dearborn, Michigan, 48124
Cancer Care Center of Decatur
Decatur, Illinois, 62526
Central Illinois CCOP
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Porter Adventist Hospital
Denver, Colorado, 80210
Exempla Saint Joseph Hospital
Denver, Colorado, 80218
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Rose Medical Center
Denver, Colorado, 80220
Colorado Cancer Research Program CCOP
Denver, Colorado, 80224-2522
Colorado Blood Cancer Institute
Denver, Colorado, 80907
Henry Ford Hospital
Detroit, Michigan, 48202
Saint John Hospital and Medical Center
Detroit, Michigan, 48236
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Mercy Medical Center
Durango, Colorado, 81301
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, 29640
Marshfield Clinic Cancer Center at Sacred Heart
Eau Claire, Wisconsin, 54701
Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Swedish Medical Center-Edmonds
Edmonds, Washington, 98026
Crossroads Cancer Center
Effingham, Illinois, 62401
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Elkhart Clinic
Elkhart, Indiana, 46514-2098
Michiana Hematology Oncology PC-Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Union Hospital of Cecil County
Elkton, Maryland, 21921
Arnot Ogden Medical Center
Elmira, New York, 14905
Hematology Oncology Center Incorporated
Elyria, Ohio, 44035
Mercy Cancer Center-Elyria
Elyria, Ohio, 44035
Newman Regional Health
Emporia, Kansas, 66801
Comprehensive Cancer Care and Research Institute of Colorado LLC
Englewood, Colorado, 80113
Swedish Medical Center
Englewood, Colorado, 80113
Green Bay Oncology - Escanaba
Escanaba, Michigan, 49431
Eureka Hospital
Eureka, Illinois, 61530
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Providence Regional Cancer Partnership
Everett, Washington, 98201
Oncology Hematology Care Inc-Healthplex
Fairfield, Ohio, 45014
Roger Maris Cancer Center
Fargo, North Dakota, 58122
Sanford Clinic North-Fargo
Fargo, North Dakota, 58122
Sanford Medical Center-Fargo
Fargo, North Dakota, 58122
Saint Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Hospital
Findlay, Ohio, 45840
Hurley Medical Center
Flint, Michigan, 48502
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Poudre Valley Hospital
Fort Collins, Colorado, 80524
McFarland Clinic PC-Trinity Cancer Center
Fort Dodge, Iowa, 50501
Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Fort Wayne Medical Oncology and Hematology Inc-Parkview
Fort Wayne, Indiana, 46845
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Frederick Memorial Hospital
Frederick, Maryland, 21701
Fredericksburg Oncology Inc
Fredericksburg, Virginia, 22401
Illinois CancerCare Galesburg
Galesburg, Illinois, 61401
Illinois CancerCare-Galesburg Cottage Plaza Office
Galesburg, Illinois, 61401
Saint Catherine Hospital
Garden City, Kansas, 67846
Glens Falls Hospital
Glens Falls, New York, 12801
Mountain Blue Cancer Care Center
Golden, Colorado, 80401
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, 27534
Wayne Memorial Hospital
Goldsboro, North Carolina, 27534
Genesys Regional Medical Center
Grand Blanc, Michigan, 48439
Altru Cancer Center
Grand Forks, North Dakota, 58201
Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Saint Rose Ambulatory and Surgery Center
Great Bend, Kansas, 67530
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Big Sky Oncology
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Saint Vincent Hospital
Green Bay, Wisconsin, 54301
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Cone Health Cancer Center
Greensboro, North Carolina, 27403
Wayne Hospital
Greenville, Ohio, 45331
Saint Francis Hospital
Greenville, South Carolina, 29601
Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Greenville Memorial Hospital
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute/Eastside
Greenville, South Carolina, 29615
Breast Cancer Care Consultants
Greenwood Village, Colorado, 80111
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, 29650
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Illinois CancerCare-Havana
Havana, Illinois, 62644
Mason District Hospital
Havana, Illinois, 62644
Hays Medical Center
Hays, Kansas, 67601
Saint Peter's Community Hospital
Helena, Montana, 59601
Hendersonville Hematology and Oncology at Pardee
Hendersonville, North Carolina, 28739
Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Park Ridge Hospital Breast Health Center
Hendersonville, North Carolina, 28792
Hematology Oncology Associates of Illinois-Highland Park
Highland Park, Illinois, 60035
Memorial Healthcare System - Joe DiMaggio Children's Hospital
Hollywood, Florida, 33021
Oncare Hawaii Inc-POB II
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
OnCare Hawaii-Liliha
Honolulu, Hawaii, 96817-3169
Kuakini Medical Center
Honolulu, Hawaii, 96817
Oncare Hawaii Inc-Kuakini
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
New Hampshire Oncology Hematology Associates
Hooksett, New Hampshire, 03106
Baylor College of Medicine
Houston, Texas, 77030
Ben Taub General Hospital
Houston, Texas, 77030
Veterans Administration Medical Center
Houston, Texas, 77030
Promise Regional Medical Center-Hutchinson
Hutchinson, Kansas, 65702
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Centerpoint Medical Center LLC
Independence, Missouri, 64057
Franciscan Saint Francis Health-Indianapolis
Indianapolis, Indiana, 46237
Green Bay Oncology - Iron Mountain
Iron Mountain, Michigan, 49801
Swedish Cancer Institute-Issaquah
Issaquah, Washington, 98029
Allegiance Health
Jackson, Michigan, 49201
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, 28546
McFarland Clinic PC-Jefferson
Jefferson, Iowa, 50129
Capital Region Medical Center-Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Freeman Health System
Joplin, Missouri, 64804
Jupiter Medical Center
Jupiter, Florida, 33458
Castle Medical Center
Kailua, Hawaii, 96734
Borgess Medical Center
Kalamazoo, Michigan, 49001
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Presence Saint Mary's Hospital
Kankakee, Illinois, 60901
Kansas City Cancer Center-West
Kansas City, Kansas, 66112
Providence Medical Center
Kansas City, Kansas, 66112
University of Kansas Medical Center
Kansas City, Kansas, 66160
Truman Medical Center
Kansas City, Missouri, 64108
Saint Luke's Cancer Institute
Kansas City, Missouri, 64111
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
North Kansas City Hospital
Kansas City, Missouri, 64116
Heartland Hematology and Oncology Associates Incorporated
Kansas City, Missouri, 64118
Kansas City Cancer Center - South
Kansas City, Missouri, 64131
Research Medical Center
Kansas City, Missouri, 64132
Kansas City Cancer Centers - North
Kansas City, Missouri, 64154
Good Samaritan Hospital
Kearney, Nebraska, 68847
Columbia Basin Hematology and Oncology PLLC
Kennewick, Washington, 99336
Kettering Medical Center
Kettering, Ohio, 45429
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Kinston Medical Specialists PA
Kinston, North Carolina, 28501
Cascade Cancer Center
Kirkland, Washington, 98034
Community Howard Regional Health
Kokomo, Indiana, 46904
Gundersen Lutheran
La Crosse, Wisconsin, 54601
Adventist La Grange Memorial Hospital
La Grange, Illinois, 60525
IU Health La Porte Hospital
La Porte, Indiana, 46350
Providence Regional Cancer System-Lacey
Lacey, Washington, 98503
LRGHealthcare-Lakes Region General Hospital
Laconia, New Hampshire, 03246
Rocky Mountain Cancer Centers-Lakewood
Lakewood, Colorado, 80228
Saint Anthony Hospital
Lakewood, Colorado, 80228
Saint Clare Hospital
Lakewood, Washington, 98499
Lancaster General Hospital
Lancaster, Pennsylvania, 17604
Sparrow Hospital
Lansing, Michigan, 48912
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Kansas City Cancer Center-Lee's Summit
Lee's Summit, Missouri, 64064
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Beebe Medical Center
Lewes, Delaware, 19958
Saint Joseph Regional Medical Center
Lewiston, Idaho, 83501
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67901
Liberty Hospital
Liberty, Missouri, 64068
North Shore Hematology Oncology
Libertyville, Illinois, 60048
Wilcox Memorial Hospital and Kauai Medical Clinic
Lihue, Hawaii, 96766
Saint Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Littleton Adventist Hospital
Littleton, Colorado, 80122
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Monmouth Medical Center
Long Branch, New Jersey, 07740
Longmont United Hospital
Longmont, Colorado, 80501
Rocky Mountain Cancer Centers-Longmont
Longmont, Colorado, 80501
Saint John Medical Center
Longview, Washington, 98632
Los Angeles County-USC Medical Center
Los Angeles, California, 90033
University of Southern California/Norris Cancer Center
Los Angeles, California, 90033
McKee Medical Center
Loveland, Colorado, 80539
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Mcdonough District Hospital
Macomb, Illinois, 61455
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
Cancer Center of Kansas-Manhattan
Manhattan, Kansas, 66502
Holy Family Memorial Hospital
Manitowoc, Wisconsin, 54221
Bay Area Medical Center
Marinette, Wisconsin, 54143
McFarland Clinic PC-Marshalltown
Marshalltown, Iowa, 50158
Marshfield Clinic
Marshfield, Wisconsin, 54449
Saint Joseph's Hospital
Marshfield, Wisconsin, 54449
Fremont - Rideout Cancer Center
Marysville, California, 95901
Toledo Clinic Cancer Centers-Maumee
Maumee, Ohio, 43537
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
Maumee, Ohio, 43537
Loyola University Medical Center
Maywood, Illinois, 60153
Cancer Center of Kansas - McPherson
McPherson, Kansas, 67460
Idaho Urologic Institute-Meredian
Meridian, Idaho, 83642
Premier Oncology Hematology Associates
Merrillville, Indiana, 46410
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
Memorial Regional Cancer Center Day Road
Mishawaka, Indiana, 46544
Michiana Hematology Oncology PC-Mishawaka
Mishawaka, Indiana, 46545-1470
Saint Joseph Regional Medical Center-Mishawaka
Mishawaka, Indiana, 46545-1470
Cancer Care Partners LLC
Mishawaka, Indiana, 46545
Montana Cancer Specialists
Missoula, Montana, 59802
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, 36688
About this study
Official title: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective in treating tumor cells.
PURPOSE: This randomized phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil work compared to irinotecan hydrochloride and docetaxel in treating patients with esophageal cancer, gastric cancer, or gastroesophageal junction cancer.
Read the detailed description
OBJECTIVES:
- To assess progression-free survival of high-excision repair cross-complementing 1(ERCC1) patients with advanced or metastatic cancer of the esophagus, stomach, or gastroesophageal junction (GEJ) treated with FOLFOX comprising oxaliplatin, leucovorin calcium, and fluorouracil compared to those treated with irinotecan hydrochloride plus docetaxel.
- To assess progression-free survival of low-ERCC1 patients with advanced or metastatic cancer of the esophagus, stomach, or GEJ treated with FOLFOX compared to those treated with irinotecan hydrochloride plus docetaxel.
- To assess progression-free survival of low-ERCC1 patients with advanced or metastatic cancer of the esophagus, stomach, or GEJ treated with FOLFOX compared to high-ERCC1 patients treated with FOLFOX.
- To assess overall survival of and toxicities in each of the two treatment arms in this group of patients.
- To assess the response probability (confirmed and unconfirmed, complete and partial responses) in the subset of patients with measurable disease in each of the two treatment arms.
- To explore whether there is evidence of interaction between treatment arm and ERCC1 expression in this group of patients. (Exploratory)
- To bank tissue and blood for future translational medicine studies; a) To explore the relationship of ERCC-1 and ERCC-2 single nucleotide polymorphism (SNP) genotypes with clinical outcome in these patients; and b) To explore the association between germline variations in these SNPs and ERCC-1 mRNA expression in these patients. (Exploratory)
OUTLINE: This is a multicenter study. Patients are stratified according to ERCC1 expression (high [≥ 1.7] vs low [< 1.7]), and disease site (esophageal vs gastric/gastroesophageal junction). Patients are randomized to 1 of 2 treatment arms.
- Arm I (FOLFOX): Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Blood and tumor tissue samples may be collected for ERCC1 expression analysis and future research studies.
After completion of study treatment, patients are followed up every 3 months for up to 3 years.
- Being tested
- FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Keywords
- recurrent esophageal cancer, stage IV esophageal cancer, recurrent gastric cancer, stage IV gastric cancer, adenocarcinoma of the gastroesophageal junction, stage IIIB gastric cancer, stage IIIC gastric cancer, stage IIIB esophageal cancer, stage IIIC esophageal cancer, adenocarcinoma of the esophagus, adenocarcinoma of the stomach
- Medical subject headings
- Esophageal Neoplasms, Stomach Neoplasms, Adenocarcinoma Of Esophagus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FOLFOX regimenDrug
Given IV. Fluorouracil, oxaliplatin, \& leucovorin calcium.
docetaxelDrug
Also called Taxotere, RP56976, NSC-628503
30 mg/m^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
fluorouracilDrug
Also called 5-fluorouracil, 5-FU, NSC-19893
400 mg/m^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
Also called CPT-11, NSC-616348
65 mg/m^2, IV over 90 minutes on Days 1 \& 8 of every 21 day cycle.
Also called NSC-3590
400 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle.
oxaliplatinDrug
Also called Eloxatin, NSC-266046
85 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle.
| Study group | Role | What they receive |
|---|---|---|
| Arm I | Experimental | FOLFOX regimen: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Receives: Drug: FOLFOX regimen; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin |
| Arm II | Experimental | Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Receives: Drug: docetaxel; Drug: irinotecan hydrochloride |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-free Survival (PFS) in High-ERCC1 Patients
Progression-free survival is the length of time between protocol registration and disease progression or death, whichever occurs first.
Measured: Up to 3 years after registration
PFS in Low-ERCC1 Participants
Progression-free survival is the length of time between protocol registration and disease progression or death, whichever occurs first.
Measured: Up to 3 years after registration
Overall Survival (OS)
OS is the length of time between protocol registration and patient death
Measured: Up to 3 years after registration
Secondary outcomes (3)
Overall Response Rate (ORR)
ORR (complete response, unconfirmed complete response, partial response, unconfirmed partial response) in patients with measurable disease were assessed in each arm and compared between arms using Chi-squared test.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Measured: Up to 3 years after registration
PFS Variation by ERCC1
Progression-free survival is the length of time between protocol registration and disease progression or death, whichever occurs first.
Participants were divided into subgroups according to ERCC1 quartiles to assess whether the differences in PFS between the two treatment arms varied by ERCC1 levels.
Measured: up to 3 years after registration
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.
Measured: Duration of treatment and follow up until death or 3 years post registration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2011 (estimated)
- Study startFeb 2012
- Primary completionMar 2018
- Study completion19 Sep 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Adenocarcinoma of the Gastroesophageal JunctionStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 213 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Syma Iqbal, MD, Principal investigator, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01498289
- Sponsor's protocol ID
- S1201
- Other IDs
- S1201, U10CA032102, NCI-2012-00096
- Status last verified
- Oct 2019
- First submitted
- 22 Dec 2011
- Last updated
- 7 Nov 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 7 Nov 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer
- ClinicalTrials.gov ID
- NCT01498289
- Acronym / sponsor ID
- S1201
- Keywords
- recurrent esophageal cancer, stage IV esophageal cancer, recurrent gastric cancer, stage IV gastric cancer, adenocarcinoma of the gastroesophageal junction, stage IIIB gastric cancer, stage IIIC gastric cancer, stage IIIB esophageal cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 213 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Feb 2012 (actual)
- Primary completion
- Mar 2018 (actual)
- Study completion
- 19 Sep 2019 (actual)
- First posted
- 23 Dec 2011 (estimated)
- Results
- Posted 29 Aug 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective in treating tumor cells.
PURPOSE: This randomized phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil work compared to irinotecan hydrochloride and docetaxel in treating patients with esophageal cancer, gastric cancer, or gastroesophageal junction cancer.
Detailed description
OBJECTIVES:
- To assess progression-free survival of high-excision repair cross-complementing 1(ERCC1) patients with advanced or metastatic cancer of the esophagus, stomach, or gastroesophageal junction (GEJ) treated with FOLFOX comprising oxaliplatin, leucovorin calcium, and fluorouracil compared to those treated with irinotecan hydrochloride plus docetaxel.
- To assess progression-free survival of low-ERCC1 patients with advanced or metastatic cancer of the esophagus, stomach, or GEJ treated with FOLFOX compared to those treated with irinotecan hydrochloride plus docetaxel.
- To assess progression-free survival of low-ERCC1 patients with advanced or metastatic cancer of the esophagus, stomach, or GEJ treated with FOLFOX compared to high-ERCC1 patients treated with FOLFOX.
- To assess overall survival of and toxicities in each of the two treatment arms in this group of patients.
- To assess the response probability (confirmed and unconfirmed, complete and partial responses) in the subset of patients with measurable disease in each of the two treatment arms.
- To explore whether there is evidence of interaction between treatment arm and ERCC1 expression in this group of patients. (Exploratory)
- To bank tissue and blood for future translational medicine studies; a) To explore the relationship of ERCC-1 and ERCC-2 single nucleotide polymorphism (SNP) genotypes with clinical outcome in these patients; and b) To explore the association between germline variations in these SNPs and ERCC-1 mRNA expression in these patients. (Exploratory)
OUTLINE: This is a multicenter study. Patients are stratified according to ERCC1 expression (high [≥ 1.7] vs low [< 1.7]), and disease site (esophageal vs gastric/gastroesophageal junction). Patients are randomized to 1 of 2 treatment arms.
- Arm I (FOLFOX): Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Blood and tumor tissue samples may be collected for ERCC1 expression analysis and future research studies.
After completion of study treatment, patients are followed up every 3 months for up to 3 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I | Experimental | Drug: FOLFOX regimen, Drug: fluorouracil, Drug: leucovorin calcium, Drug: oxaliplatinFOLFOX regimen: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. |
| Arm II | Experimental | Drug: docetaxel, Drug: irinotecan hydrochloridePatients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FOLFOX regimenGiven IV. Fluorouracil, oxaliplatin, \& leucovorin calcium. | Drug | Arm I |
| docetaxelAlso: Taxotere, RP56976, NSC-62850330 mg/m^2, IV over 30 minutes on Day 1,8 of each 21 day cycle. | Drug | Arm II |
| fluorouracilAlso: 5-fluorouracil, 5-FU, NSC-19893400 mg/m^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle. | Drug | Arm I |
| irinotecan hydrochlorideAlso: CPT-11, NSC-61634865 mg/m^2, IV over 90 minutes on Days 1 \& 8 of every 21 day cycle. | Drug | Arm II |
| leucovorin calciumAlso: NSC-3590400 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle. | Drug | Arm I |
| oxaliplatinAlso: Eloxatin, NSC-26604685 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle. | Drug | Arm I |
Primary outcome
Progression-free Survival (PFS) in High-ERCC1 Patients
Time frame: Up to 3 years after registration
Progression-free survival is the length of time between protocol registration and disease progression or death, whichever occurs first.
PFS in Low-ERCC1 Participants
Time frame: Up to 3 years after registration
Progression-free survival is the length of time between protocol registration and disease progression or death, whichever occurs first.
Overall Survival (OS)
Time frame: Up to 3 years after registration
OS is the length of time between protocol registration and patient death
3 secondary outcomes
Overall Response Rate (ORR)
Time frame: Up to 3 years after registration
PFS Variation by ERCC1
Time frame: up to 3 years after registration
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Time frame: Duration of treatment and follow up until death or 3 years post registration
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Nov 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Adenocarcinoma of the Gastroesophageal Junction
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 2
Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric or Gastroesophageal Junction Adenocarcinoma
Active, not recruitingPhase 2
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Active, not recruiting
Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery
Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
RecruitingPhase 1/2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Syma Iqbal, MD principal investigator
University of Southern California
508 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing FOLFOX regimen, docetaxel and fluorouracil in people with Adenocarcinoma of the Gastroesophageal Junction and Esophageal Cancer, run by SWOG Cancer Research Network at 508 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 508 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 29 Aug 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-free Survival (PFS) in High-ERCC1 Patients (time frame: Up to 3 years after registration). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2019.